Rational prescribing of antibacterials in hospitalised children

PharmacoEconomics

Volumn 10, Issue 6, 1996, Pages 575-593

  Hoppe, Jörg E ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; CEFMENOXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORIN; CLINDAMYCIN; ERYTHROMYCIN GLUCOHEPTONATE; ERYTHROMYCIN LACTOBIONATE; FLUCLOXACILLIN; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; MACROLIDE; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

CHILD; HOSPITAL PATIENT; HUMAN; INFECTION; PEDIATRICS; PHARMACOECONOMICS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

EID: 0029802127     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199610060-00005     Document Type: Review

References (121)

1. Louie TJ. Intravenous to oral stepdown antibiotic therapy: another cost-effective strategy in an era of shrinking health care dollars. Can J Infect Dis 1994; 5 Suppl. C: 45C-50C
2. Eisenberg JM. Clinical economics. JAMA 1989; 262: 2879-86
3. Kaplan JM, Goretski SA, Keith S, et al. Cost of antibiotic therapy for infants and children. Pediatr Infect Dis J 1990; 9: 722-8
4. Blumer JL. Carbapenems in paediatrics. Scand J Infect Dis 1995; Suppl. 96: 38-44
5. Quintiliani R, Cooper BW, Briceland LL, et al. Economic impact of streamlining antibiotic administration. Am J Med 1987; 82 Suppl. 4A: 391-4
6. Balinsky W, Nesbitt S. Cost-effectiveness of outpatient parenteral antibiotics: a review of the literature. Am J Med 1989; 87: 301-5
7. Williams DN, Bosch D, Boots J, et al. Safety, efficacy, and cost savings in an outpatient intravenous antibiotic program. Clin Ther 1993; 15: 169-79
8. Craig WA. Outpatient parenteral antibiotic therapy-introduction. Eur J Clin Microbiol Infect Dis 1995; 14: 635
9. Dagan R, Einhorn M. A program of outpatient parenteral antibiotic therapy for serious pediatric bacterial infections. Rev Infect Dis 1991; 13 Suppl. 2: S152-5
10. Nelson JD. Options for outpatient management of serious infections. Pediatr Infect Dis J 1992; 11: 175-8
11. Craig WA. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. Eur J Clin Microbiol Infect Dis 1995; 14: 636-42
12. Janknegt R, van der Meer JWM. Antimicrobial practice: sequential therapy with intravenous and oral cephalosporins. J Antimicrob Chemother 1994; 33: 169-77
13. Bradley JS, Ching DK, Hart CL. Invasive bacterial disease in childhood: efficacy of oral antibiotic therapy following short course parenteral therapy in non-central nervous system infections. Pediatr Infect Dis J 1987; 6: 821-5
14. Dagan R, Syrogiannopoulos G, Ashkenazi S, et al. Parenteral-oral switch in the management of paediatric pneumonia. Drugs 1994; 47 Suppl. 3: 43-51
15. Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 1995; 29: 561-5
16. Kaplan EL. Benzathine penicillin G for treatment of group A streptococcal pharyngitis: a reappraisal in 1985. Pediatr Infect Dis 1985; 4: 592-6
17. Schreiber JR, Jacobs MR. Antibiotic-resistant pneumococci. Pediatr Clin North Am 1995; 42: 519-37
18. Saez-Nieto JA, Lujan R, Berron S, et al. Epidemiology and molecular basis of penicillin-resistant Neisseria meningitidis in Spain: a 5-year history (1985-1989). Clin Infect Dis 1992; 14: 394-402
19. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986; 108: 835-40
20. Wise R. Antimicrobial agents: a widening choice. Lancet 1987; 11: 1251-4
21. Lieberman JM, Stutman HR. Advances in pediatric antibiotic therapy. In: Engelhard D, Marks MI, Branski D, editors. Pediatric infectious diseases. Vol. 4. Basel: Karger, 1993: 1-14
22. Neu HC. Antistaphylococcal penicillins. Med Clin North Am 1982; 66: 51-60
23. Sutherland R. Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications. Infection 1995; 23: 191-200
24. Goldfarb J. New antimicrobial agents. Pediatr Clin North Am 1995; 42: 717-35
25. Schaad UB, Suter S, Gianella-Borradori A, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990; 322: 141-7
26. Nelson SJ, Boies EG, Shackelford PG. Ceftriaxone in the treatment of infections caused by Staphylococcus aureus in children. Pediatr Infect Dis 1985; 4: 27-31
27. Donowitz GR, Mandell GL. Beta-lactam antibiotics. N Engl J Med 1988; 318: 419-26, 490-500
28. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96
29. Higham M, Cunningham FM, Teele DW. Ceftriaxone administered once or twice a day for treatment of bacterial infections of childhood. Pediatr Infect Dis 1985; 4: 22-6
30. Dagan R, Phillip M, Watemberg NM, et al. Outpatient treatment of serious community-acquired pediatric infections using once daily intramuscular ceftriaxone. Pediatr Infect Dis J 1987; 6: 1080-4
31. Powell KP, Mawhorter SD. Outpatient treatment of serious infections in infants and children with ceftriaxone. J Pediatr 1987; 110: 898-901
32. Bradley JS, Ching DK, Phillips SE. Outpatient therapy of serious pediatric infections with ceftriaxone. Pediatr Infect Dis J 1988; 7: 160-4
33. Segev S, Raz R, Rubinstein E, et al. Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections. Eur J Clin Microbiol Infect Dis 1995; 14: 851-5
34. Poretz DM, Woolard D, Eron LJ, et al. Outpatient use of ceftriaxone: a cost-benefit analysis. Am J Med 1984; 77 Suppl. 4C: 77-80
35. Lee SP, Lipsky BA, Teefey SA. Gallbladder sludge and antibiotics. Pediatr Infect Dis J 1990; 9: 422-3
36. Dagan R, Fliss DM, Einhorn M, et al. Outpatient management of chronic suppurative otitis media without cholesteatoma in children. Pediatr Infect Dis J 1992; 11: 542-6
37. Kovarik JM, Hoepelman IM, Verhoef J. Once-daily aminoglycoside administration: new strategies for an old drug. Eur J Clin Microbiol Infect Dis 1989; 8: 761-9
38. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991; 35: 399-405
39. Blaser J, König C. Once-daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis 1995; 14: 1029-38
40. Wallen L, Zeller WP, Goessler M, et al. Single-dose amikacin treatment of first childhood E. coli lower urinary tract infections. J Pediatr 1983; 103: 316-9
41. Schaad UB, McCracken GH, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980; 96: 119-26
42. Trautmann M, Wiedeck H, Ruhnke M, et al. Teicoplanin: 10 years of clinical experience. Infection 1994; 22: 430-6
43. Dagan R, Einhorn M, Howard CB, et al. Infections due to Gram-positive organisms in children: possible role for teicoplanin. J Antimicrob Chemother 1991; 27 Suppl.B: 37-41
44. Peller P, Aichholzer B, Fell J, et al. Safety and efficacy of teicoplanin in the treatment of Gram-positive infections in pediatric patients in Germany. Pediatr Infect Dis J 1993; 12: S7-9
45. Dagan R, Einhorn M, Howard CB, et al. Outpatient and inpatient teicoplanin treatment for serious Gram-positive infections in children. Pediatr Infect Dis J 1993; 12: S17-20
46. Schaison GS. Cost effectiveness of teicoplanin plus ceftriaxone: a once daily antibiotic regimen. Pediatr Infect Dis J 1993; 12: S14-6
47. Moellering RC. Editorial: monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 1994; 18: 544-6
48. Murphy S, Pinney RJ. Teicoplanin or vancomycin in the treatment of Gram-positive infections? J Clin Pharm Ther 1995; 20: 5-11
49. Wilson APR, Grüneberg RN. Use of teicoplanin in community medicine. Eur J Clin Microbiol Infect Dis 1994; 13: 701-10
50. Spencer CM, Bryson HM. Teicoplanin: a pharmacoeconomic evaluation of its use in the treatment of Gram-positive infections. Pharmacoeconomics 1995; 7: 357-74
51. Eichenwald HF. Adverse reactions to erythromycin. Pediatr Infect Dis 1986; 5: 147-50
52. LeFrock JL, Molavi A, Prince RA. Clindamycin. Med Clin North Am 1982; 66: 103-20
53. Cunha BA, Sibley CM, Ristuccia AM. Doxycycline. Ther Drug Monit 1982; 4: 115-35
54. Feder HM, Osier C, Maderazo EG. Chloramphenicol: a review of its use in clinical practice. Rev Infect Dis 1981; 3: 479-91
55. Tunkel AR, Wispelwey B, Scheld WM. Bacterial meningitis: recent advances in pathophysiology and treatment. Ann Intern Med 1990; 112: 610-23
56. Tunkel AR, Scheld WM. Acute bacterial meningitis. Lancet 1995; 346: 1675-80
57. McCracken GH. Current management of bacterial meningitis in infants and children. Pediatr Infect Dis J 1992; 11: 169-74
58. Jordens JZ, Slack MPE. Haemophilus influenzae: then and now. Eur J Clin Microbiol Infect Dis 1995; 14: 935-48
59. Scheid WM. Rationale for optimal dosing of beta-lactam antibiotics in therapy for bacterial meningitis. Eur J Clin Microbiol 1984; 3: 579-91
60. Botha P. Penicillin-resistant Neisseria meningitidis in Southern Africa [letter]. Lancet 1988; 1: 54
61. Campos J, Trujillo G, Seuba T, et al. Discriminative criteria for Neisseria meningitidis isolates that are moderately susceptible to penicillin and ampicillin. Antimicrob Agents Chemother 1992; 36: 1028-31
62. de Groot R, Dzoljic-Danilovic D, van Klingeren K, et al. Antibiotic resistance in Haemophilus influenzae: mechanisms, clinical importance and consequences for therapy. Eur J Pediatr 1991; 150: 534-46
63. Jorgensen JH. Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae. Clin Infect Dis 1992; 14: 1119-23
64. Kayser FH, Morenzoni G, Santanam P. The second European collaborative study on the frequency of antimicrobial resistance in Haemophilus influenzae. Eur J Clin Microbiol Infect Dis 1990; 9: 810-7
65. Paris MP, Ramilo O, McCraeken GH. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1995; 39: 2171-5
66. Friedland IR, Klugman KP. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet 1992; 339: 405-8
67. Friedland IR, McCrackcn GH. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331: 377-82
68. Klugman KP, Dagan R. Carbapenem treatment of meningitis. Scand J Infect Dis 1995; Suppl.96: 45-8
69. Friedland IR, Paris M, Ehrett S, et al. Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993; 37: 1630-6
70. Radetsky M. Duration of treatment in bacterial meningitis: a historical inquiry. Pediatr Infect Dis J 1990; 9: 2-9
71. O'Neill P. How long to treat bacterial meningitis. Lancet 1993; 341: 530
72. Waler JA, Rathore MH. Outpatient management of pediatric bacterial meningitis. Pediatr Infect Dis J 1995; 14: 89-92
73. Steele RW, Marcy SM. Outpatient management of bacterial meningitis. Pediatr Infect Dis J 1984; 8: 258-60
74. Lien TA, Schwartz JS, Jaffe DM, et al. Strategies for diagnosis and treatment of children at risk for occult bacteremia: clinical effectiveness and cost-effectiveness. J Pediatr 1991; 118: 21-9
75. Dagan R, Branski D. The approach to the febrile child under 24 months of age. In: Eingelhard D, Marks MI, Branski D, editors. Pediatric infectious diseases. Pediatric and Adolescent Medicine. Vol. 4. Basel: Karger, 1993: 120-9
76. Fleisher GR. Management of children with occult bacteremia who are treated in the emergency department. Rev Infect Dis 1991; 13 Suppl.2: S156-9
77. Fleisher GR, Rosenberg N, Vinci R, et al. Intramuscular versus oral antibiotic therapy for the prevention of meningitis and other bacterial sequelae in young, febrile children at risk for occult bacteremia. J Pediatr 1994; 124: 504-12
78. Bass JW, Steele RW, Wittler RR, et al. Antimicrobial treatment of occult bacteremia: a multicenter cooperative study. Pediatr Infect Dis J 1993; 12: 466-73
79. Starke JR. Infective endocarditis. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. Philadelphia: WB Saunders, 1992: 326-43
80. Bisno AL, Dismukes WE, Durack DT, et al. Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci. JAMA 1989; 261: 1471-7
81. Baltimore RS. Infective endocarditis in children. Pediatr Infect Dis J 1992; 11: 907-12
82. Working Party of the British Society for Antimicrobial Chemotherapy. Antibiotic treatment of streptococcal and staphylococcal endocarditis. Lancet 1985; 11: 815-7
83. Niebel J. Empfehlungen zur Behandlung der infektiösen Endokarditis. Dtsch Med Wochenschr 1990; 115: 1110-8
84. Stamboulian D. Outpatient treatment of endocarditis in a clinic-based program in Argentina. Eur J Clin Microbiol Infect Dis 1995; 14: 648-54
85. Syriopoulou VP, Smith AL. Osteomyelitis and septic arthritis. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. Philadelphia: WB Saunders, 1992: 727-40
86. Prober CG. Current antibiotic therapy of community-acquired bacterial infections in hospitalized children: bone and joint infections. Pediatr Infect Dis J 1992; 11: 156-9
87. Dagan R. Management of acute hematogenous osteomyelitis and septic arthritis in the pediatric patient. Pediatr Infect Dis J 1993; 12: 88-93
88. Nelson JD. Acute osteomyelitis in children. Infect Dis Clin North Am 1990; 4: 513-22
89. Kaplan SL. Acute osteomyelitis. In: Kaplan SL, editor. Current therapy in pediatric infectious disease. St. Louis: Mosby-Year Book, 1993: 101-3
90. Rodriguez W, Ross S, Khan W, et al. Clindamycin in the treatment of osteomyelitis in children. Am J Dis Child 1977; 131: 1088-93
91. Wharton MR, Beddow FH. Clindamycin for acute osteomyelitis in children. Postgrad Med J 1975; 51: 166-8
92. LeFrock JL, Mader J, Smith B, et al. Bone and joint infections caused by Gram-positive bacteria: treatment with cefotaxime. Infection 1985; 13 Suppl.1: S50-5
93. Nelson JD, Bucholz RW, Kusmiesz, H, et al. Benefits and risks of sequential parenteral-oral cephalosporin therapy for suppurative bone and joint infections. J Pediatr Orthop 1982; 2: 255-62
94. Eisenberg JM, Kitz DS. Savings from outpatient antibiotic therapy for osteomyelitis. JAMA 1986; 255: 1584-8
95. Syriopoulou VP, Smith AL. Septic arthritis. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. Philadelphia: WB Saunders, 1992: 740-6
96. Kaplan SL. Suppurative arthritis. In: Kaplan SL, editor. Current therapy in pediatric infectious disease. St. Louis: Mosby-Year Book, 1993: 99-101
97. Leung AKC, Robson WLM. Urinary tract infection in infancy and childhood. Adv Pediatr 1991; 38: 257-81
98. Marks MI, Arrieta AC. Pyelonephritis. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. Philadelphia: WB Saunders, 1992: 487-94
99. Shapiro ED. Infections of the urinary tract. Pediatr Infect Dis J 1992; 11: 165-8
100. McCracken GH. Options in antimicrobial management of urinary tract infections in infants and children. Pediatr Infect Dis J 1989; 8: 552-5
101. Sherbotie JR, Cornfeld D. Management of urinary tract infections in children. Med Clin North Am 1991; 75: 327-38
102. Eichenwald HF. Some aspects of the diagnosis and management of urinary tract infection in children and adolescents. Pediatr Infect Dis 1986; 5: 760-5
103. Weber K, Pfister HW. Clinical management of Lyme borreliosis. Lancet 1994; 343: 1017-20
104. Committee on Infectious Diseases. Treatment of Lyme borreliosis. Pediatrics 1991; 88: 176-9
105. Stechenberg BW. Borrelia. Lyme disease. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. Philadelphia: WB Saunders, 1992: 1062-7
106. Shapiro ED. Lyme disease. In: Kaplan SL, editor. Current therapy in pediatric infectious disease. St. Louis: Mosby-Year Book, 1993: 217-9
107. Christen HJ, Hanefeld F, Eiffert H, et al. Epidemiology and clinical manifestations of Lyme borreliosis in childhood. Acta Paediatr Suppl 1993; 82: 1-75
108. Eichenfield AH, Goldsmith DP, Benach JL, et al. Childhood Lyme arthritis: experience in an endemic area. J Pediatr 1986; 109: 753-8
109. Culp RW, Eichenfield AH, Davidson RS, et al. Lyme arthritis in children. J Bone Joint Surg 1987; 69-A: 96-9
110. Huppertz HI, Karch H, Suschke HJ, et al. Lyme arthritis in European children and adolescents. Arthritis Rheum 1995; 38: 361-8
111. Evans HE, Turcios NL. Infections of the lower respiratory tract in infancy and early childhood. In: Pennington JE, editor. Respiratory infections: diagnosis and management. New York: Raven Press, 1994: 229-55
112. Editorial. Pneumonia in childhood. Lancet 1988; 1: 741-3
113. Schutze GE, Jacobs RF. Management of community-acquired bacterial pneumonia in hospitalized children. Pediatr Infect Dis J 1992; 11: 160-4
114. Long SS. Treatment of acute pneumonia in infants and children. Pediatr Clin North Am 1983; 30: 297-321
115. Teele D. Pneumonia: antimicrobial therapy for infants and children. Pediatr Infect Dis 1985; 4: 330-5
116. Dagan R. Antibiotic treatment of pediatric community-acquired lower respiratory tract infections: challenges and possible solutions. Respiration 1993; 60 Suppl.1: 38-44
117. Wald ER. Acute pneumonia of unknown etiology. In: Kaplan SL, editor. Current therapy in pediatric infectious disease. St. Louis: Mosby-Year Book, 1993: 57-9
118. Rettig PJ. Chlamydial infections in pediatrics: diagnostic and therapeutic considerations. Pediatr Infect Dis 1986; 5: 158-62
119. Lister PD. Multiply-resistant pneumococcus: therapeutic problems in the management of serious infections. Eur J Clin Microbiol Infect Dis 1995; 14 Suppl.1: S18-25
120. Klugman KP. Antibiotic-resistant pneumococci: epidemiology and treatment of pneumonia. Chemother J 1995; 4: 19-22
121. Leibovitz E, Tabachnik E, Fliedel O, et al. Once-daily intramuscular ceftriaxone in the outpatient treatment of severe community-acquired pneumonia in children. Clin Pediatr 1990; 29: 634-9